Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas C Ray

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Bioorganic & Medicinal Chemistry Letters|April 15, 2019
Discovery of a class of highly potent Janus Kinase 1/2 (JAK1/2) inhibitors demonstrating effective cell-based blockade of IL-13 signalingMark Zak, Emily J Hanan, Patrick Lupardus, et al.
Science Translational Medicine|November 23, 2018
Lung-restricted inhibition of Janus kinase 1 is effective in rodent models of asthmaHart S Dengler, Xiumin Wu, Ivan Peng, et al.
Journal of Medicinal Chemistry|July 12, 2021
GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast CancerJun Liang, Jason R Zbieg, Robert A Blake, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Bioorganic & Medicinal Chemistry Letters|April 15, 2019
Discovery of a class of highly potent Janus Kinase 1/2 (JAK1/2) inhibitors demonstrating effective cell-based blockade of IL-13 signalingMark Zak, Emily J Hanan, Patrick Lupardus, et al.
Science Translational Medicine|November 23, 2018
Lung-restricted inhibition of Janus kinase 1 is effective in rodent models of asthmaHart S Dengler, Xiumin Wu, Ivan Peng, et al.
Journal of Medicinal Chemistry|July 12, 2021
GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast CancerJun Liang, Jason R Zbieg, Robert A Blake, et al.
Pageof 2